VolitionRx Achieves Breakthrough in Liquid Biopsy Technology With Over 99% Cancer DNA Purity

VolitionRx Limited (NYSE American: VNRX) announced a breakthrough in liquid biopsy technology, achieving over 99% purity in isolating circulating tumor-derived DNA using its Capture-Seq(TM) platform. This advancement overcomes a longstanding challenge of distinguishing cancer DNA from healthy cell-free DNA in blood samples. The company reported strong early validation results, including no false positives and successful detection across initial study cohorts, supporting the potential of the technology as a novel biomarker approach.

The company said the advancement could support applications in multi-cancer early detection and minimal residual disease monitoring, representing a combined total addressable market of approximately $36 billion. Volition added that it is in active discussions with global diagnostic and liquid biopsy companies to accelerate development and commercialization of the platform. This breakthrough matters because liquid biopsies represent a less invasive alternative to traditional tissue biopsies, potentially enabling earlier cancer detection and more frequent monitoring of disease progression or treatment response.

The implications of this announcement are significant for the field of oncology diagnostics. High purity in isolating cancer DNA reduces the risk of false positives and improves the accuracy of detection, which is critical for reliable early-stage cancer screening. The technology's potential application in minimal residual disease monitoring could help clinicians assess treatment effectiveness and detect cancer recurrence earlier than current methods allow. For more information about the company, visit https://volition.com/.

The advancement also highlights the growing importance of epigenetics in cancer diagnostics. By focusing on epigenetic markers rather than genetic mutations alone, Volition's approach may detect cancers that other liquid biopsy methods miss. The company's active discussions with global diagnostic firms suggest potential for rapid commercialization and integration into clinical practice. This development comes at a time when the liquid biopsy market is expanding rapidly, driven by demand for non-invasive cancer detection methods.

The breakthrough's importance extends beyond technical achievement to potential patient impact. Earlier cancer detection typically leads to better treatment outcomes and survival rates, while improved monitoring could help personalize cancer therapies. The reported 99% purity level represents a substantial improvement over existing technologies, which often struggle with background noise from healthy DNA. If successfully commercialized, this technology could make routine cancer screening more accessible and reliable, potentially transforming cancer care paradigms. The press release detailing this advancement can be found at https://ibn.fm/1ZqGi.